Skip to main content
. 2020 Oct 26;21(21):7927. doi: 10.3390/ijms21217927

Figure 1.

Figure 1

The Effects of HMG-CoA reductase inhibitors on rat cardiac stem cell growth in vitro. (A–C) Effects of Rosuvastatin (ROSU, 1 µM), Simvastain (SIM, 1 µM) or Pravastatin (PRAVA, 5 µM) on CSC proliferation, respectively, evaluated by BrdU incorporation and growth curve at the indicated time points. * p < 0.05 vs. CTRL. Data are Mean ± SD, n = 6. (D) CSCs show a significant higher clonogenic potential when treated with Rosuvastatin (ROSU, 1 µM), Simvastain (SIM, 1 µM) or Pravastatin (PRAVA, 5 µM) as compared to untreated control cells (CTRL). * p < 0.05 vs. CTRL. Data are Mean ± SD, n = 6. (E) CSCs show a significant higher spherogenic potential (CardioSphere -CS- number) when treated with Rosuvastatin (ROSU, 1 µM), Simvastain (SIM, 1 µM) or Pravastatin (PRAVA, 5 µM) as compared to untreated control cells (CTRL). * p < 0.05 vs. CTRL. (F) Representative images of CSC-derived cardiospheres are shown in the presence or absence of SIM where number and size of spheres are increased by statins, bar = 50 μm. Data are Mean ± SD, n = 6.